Yüklüyor......
A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma
BACKGROUND: Molecular targeted therapies were found to be efficacious and safer in the treatment of metastatic renal cell carcinoma (mRCC). Sorafenib is the first target agent (TA) to report a benefit in this disease and has largely established a prominent role in progression-free survival (PFS). Ho...
Kaydedildi:
| Yayımlandı: | Medicine (Baltimore) |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wolters Kluwer Health
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6344165/ https://ncbi.nlm.nih.gov/pubmed/30608388 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000013779 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|